Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17059061 | 0.85 | NR1H4 (0.43) | EPHX2NR1H4EPHX1ALDH1A1ACACB | |
| SCHEMBL21221627 | 0.83 | EPHX1 (0.50) | EPHX2NR1H4TP53TSHREPHX1 | |
| SCHEMBL21221626 | 0.83 | EPHX1 (0.50) | EPHX2NR1H4TP53TSHREPHX1 | |
| SCHEMBL11947644 | 0.83 | CYP1A2 (0.41) | ALDH1A1LMNA | |
| SCHEMBL8540131 | 0.81 | SLC7A5 (0.51) | LMNA | |
| SCHEMBL11947645 | 0.81 | SLC7A5 (0.51) | LMNA | |
| SCHEMBL11955261 | 0.80 | LDHA (0.54) | EPHX2ALDH1A1LMNAKMT2A | |
| Carbamic Acid SCHEMBL28108890 | 0.80 | TP53 (0.47) | EPHX2NR1H4TP53TSHREPHX1 | |
| SCHEMBL11947637 | 0.80 | SLC6A4 (0.58) | EPHX2MEN1LMNAKMT2A | |
| SCHEMBL28571030 | 0.80 | ANPEP (0.46) | EPHX2NR1H4ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | disclosed |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-01-12 | — | — | US | disclosed |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
| EP-3110792-B1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-20190247356-A1 | Aminocarbonylcarbamate Compounds | SK BIOPHARMACEUTICALS CO., LTD. | 2019-08-15 | — | — | US | disclosed |
| US-10314808-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-06-11 | — | — | US | disclosed |
| US-20180085337-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-9833432-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-3110792-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK Biopharmaceuticals Co., Ltd. (KR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | disclosed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | disclosed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | disclosed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247356-A1 | Aminocarbonylcarbamate Compounds | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
| US-20180085337-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
| US-10314808-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | EPHX2 3758/4885NR1H4 2217/4885TP53 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.